US stock · Healthcare sector · Drug Manufacturers—General
Company Logo

Gilead Sciences, Inc.

GILDNASDAQ

64.80

USD
+0.33
(+0.51%)
Market Closed
18.10P/E
10Forward P/E
0.70P/E to S&P500
81.960BMarket CAP
4.44%Div Yield
Upcoming Earnings
27 Jul-1 Aug
Shares Short
5/13/22
16.85M
Short % of Float
1.34%
Short % of Shares Outs.
1.34%
% Held by Insiders
0.06%
% Held by Institutions
81.95%
Beta
0.39
PEG Ratio
-7.28
52w. high/low
74.12/57.19
Avg. Daily Volume
9.52M
Return %
Stock
S&P 500
1 year
(2.19)
(3.64)
3 years
(0.11)
43.84
5 years
0.42
68.07
Scale: |
High
Low
23.95
15.48
28.82
17.80
26.64
20.31
24.75
15.87
21.75
17.23
38.56
20.67
76.11
36.94
116.83
63.50
123.37
86.00
103.10
70.83
86.27
63.76
89.54
60.32
70.50
60.89
85.97
56.56
74.12
57.93
73.40
57.19
Currency: USD
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
TTM
Revenue per share
1.65
2.28
2.90
3.88
4.64
5.41
6.41
7.33
16.35
22.29
22.70
19.97
17.05
17.68
19.64
21.74
21.88
Earnings per share
(0.65)
0.87
1.09
1.46
1.69
1.81
1.71
2.01
7.95
12.37
10.08
3.54
4.20
4.24
0.10
4.96
3.59
FCF per share
0.61
0.91
1.13
1.58
1.62
2.26
1.85
1.91
8.06
13.38
11.89
8.65
5.76
6.55
5.98
8.60
7.93
Dividends per share
- -
- -
- -
- -
- -
- -
- -
- -
- -
1.28
1.83
2.09
2.29
2.54
2.74
2.87
2.89
CAPEX per share
0.06
0.04
0.06
0.13
0.04
0.09
0.26
0.12
0.37
0.51
0.56
0.45
0.71
0.65
0.52
0.46
0.53
Book Value per sh.
0.99
1.86
2.26
3.52
3.42
4.35
6.15
7.44
10.14
12.66
14.11
15.64
16.48
17.74
14.48
16.77
16.36
Comm.Shares outs.
1,836
1,858
1,841
1,809
1,712
1,550
1,515
1,529
1,522
1,464
1,339
1,307
1,298
1,270
1,257
1,256
1,256
Avg. annual P/E ratio
(23.8)
22.8
22.4
15.8
11.6
11.0
16.5
27.7
11.2
8.5
8.3
20.5
17.5
15.4
706.3
13.6
18.1
P/E to S&P500
(1.3)
1.3
1.0
0.2
0.6
0.7
1.1
1.6
0.6
0.4
0.4
0.9
0.7
0.6
18.7
0.5
0.7
Avg. annual div. yield
- -
- -
- -
- -
- -
- -
- -
- -
- -
1.2%
2.2%
2.9%
3.1%
3.9%
4.0%
4.3%
4.3%
Revenue (m)
3,026
4,230
5,336
7,011
7,949
8,385
9,703
11,202
24,890
32,639
30,390
26,107
22,127
22,449
24,689
27,305
27,472
Operating margin
(25.1)%
51.2%
50.2%
50.3%
49.8%
45.2%
41.3%
40.4%
61.3%
68.0%
58.0%
54.1%
37.1%
19.1%
16.5%
36.3%
26.0%
Depreciation (m)
47
51
102
213
265
302
278
345
1,050
1,098
1,158
1,286
1,429
1,404
1,480
2,050
2,102
Net profit (m)
(1,190)
1,615
2,011
2,636
2,901
2,804
2,592
3,075
12,101
18,108
13,501
4,628
5,455
5,386
123
6,225
4,515
Income tax rate
(86.5)%
28.9%
26.5%
25.0%
26.2%
23.6%
28.7%
27.3%
18.8%
16.4%
21.1%
65.7%
30.0%
(4.0)%
94.7%
25.1%
49.9%
Net profit margin
(39.3)%
38.2%
37.7%
37.6%
36.5%
33.4%
26.7%
27.4%
48.6%
55.5%
44.4%
17.7%
24.7%
24.0%
0.5%
22.8%
16.2%
Working capital (m)
1,665
2,292
3,079
2,941
3,243
11,404
1,886
948
11,953
14,872
11,226
20,188
25,231
20,537
4,599
3,162
4,071
Long-term debt (m)
1,392
1,312
1,356
1,243
2,946
7,606
7,055
3,939
11,921
21,195
26,346
30,795
24,574
22,094
28,645
25,179
25,183
Equity (m)
1,816
3,460
4,152
6,367
5,864
6,739
9,310
11,369
15,426
18,534
18,887
20,442
21,387
22,525
18,202
21,069
19,927
ROIC
(36.4)%
32.6%
36.0%
34.9%
33.6%
20.2%
17.0%
20.8%
43.6%
45.2%
30.2%
8.6%
11.7%
12.4%
0.3%
12.4%
6.3%
Return on capital
(15.8)%
39.9%
40.2%
37.5%
35.6%
22.5%
19.0%
20.5%
44.7%
43.6%
32.0%
20.8%
14.0%
10.0%
3.9%
13.7%
10.9%
Return on equity
(65.5)%
46.7%
48.4%
41.4%
49.5%
41.6%
27.8%
27.0%
78.4%
97.7%
71.5%
22.6%
25.5%
23.9%
0.7%
29.5%
22.7%
Plowback ratio
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
89.7%
81.8%
41.0%
45.5%
40.2%
(2,704.1)%
42.1%
19.4%
Div.&Repurch./FCF
- -
14.5%
82.5%
27.2%
137.1%
61.9%
7.2%
9.2%
40.9%
59.0%
83.2%
30.5%
74.7%
57.2%
63.5%
36.9%
40.7%
Capital Structure
4 May · 2022 | Q1
All numbers in millions
Total liabilities
$ 43,165
Total assets
$ 63,080
Long-term debt
$ 25,183
Cash and equiv.
$ 4,296
Goodwill
$ 8,314
Retained earnings
$ 14,986
Common stock
1,255
Enterprise Value
$ 102,847
Working Capital
Currency: USD, in millions
2019
2020
2021
Cash & Investments
24,352
7,408
6,520
Receivables
3,582
4,892
4,493
Inventory
922
1,683
1,618
Other
1,440
(3,621)
(4,152)
Current assets
30,296
15,996
14,772
Acc. Payable
713
844
705
Debt due
2,499
2,757
1,516
Other
6,547
7,796
9,389
Current liabilities
9,759
11,397
11,610
Annual growth rates
(avg. rate of change)
1 year
5 years
10 years
Revenue
10.60%
1.70%
17.18%
Cash flow
43.72%
2.87%
38.71%
Earnings
4,960.98%
1,219.97%
572.28%
Dividends
4.52%
7.20%
- -
Book value
15.75%
1.63%
10.51%
Insider Trading
Type
Shares
Date
Barton Jacqueline K
Award
15,851
05/05/22
Barton Jacqueline K
Award
2,444
05/05/22
Lofton Kevin E
Award
15,851
05/05/22
Lofton Kevin E
Award
2,444
05/05/22
Bluestone Jeffrey
Award
15,851
05/05/22
Quarterly Revenue
Currency: USD, in millions
Year
1Q
2Q
3Q
4Q
Total
2020
5,548
5,143
6,577
7,421
24,689
2021
6,423
6,217
7,421
7,244
27,305
2022
6,590
- -
- -
- -
- -
Earnings per share
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
1.23
(2.66)
0.29
1.23
0.10
2021
1.38
1.21
2.06
0.30
4.96
2022
0.02
- -
- -
- -
- -
Quarterly dividends paid
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
0.70
0.68
0.68
0.68
2.74
2021
0.73
0.71
0.72
0.71
2.87
2022
0.75
- -
- -
- -
- -
Company Description
Sector:
Healthcare
Industry:
Drug Manufacturers—General
CEO:
Mr. Daniel O'Day
Full-time employees:
14,400
City:
Foster City
Address:
333 LAKESIDE DR
IPO:
Jan 1, 1992
Website:
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
Recent News
· 30 Mar, 2022 · The Wall Street Journal
· 1 Feb, 2022 · The Wall Street Journal
· 18 Jan, 2022 · The Wall Street Journal
· 10 Dec, 2020 · The Wall Street Journal
· 20 Nov, 2020 · The Wall Street Journal
· 28 Oct, 2020 · The Wall Street Journal
· 14 Sep, 2020 · The Wall Street Journal
· 13 Sep, 2020 · The Wall Street Journal
· 30 Jul, 2020 · The Wall Street Journal
· 16 Jul, 2020 · The Wall Street Journal